The available treatment options and even the current guidelines for the management of IgA nephropathy (IgAN) come with several limitations. Fortunately, new therapies are on the horizon that can help us address those challenges and slow disease progression in IgAN. Here with Dr. Charles Turck to discuss limitations and advances in the IgAN treatment landscape is Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Medical Center in New York.